Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We investigated the effects of empagliflozin on clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.
C
hronic kidney disease (CKD) is estimated to affect >10% of the world's population. 1 In the United States, >25 million people have CKD, 2 and type 2 diabetes mellitus (T2DM) is the leading cause of this condition. 3 Approximately 40% of patients with T2DM have CKD on the basis of estimated glomerular filtration rate (eGFR) or albuminuria criteria, 4, 5 and >20% have clinically overt CKD (eGFR <60 mL·min −1 ·1.73 m −2 ). 5, 6 Cardiovascular risk, including heart failure episodes, and mortality increase as eGFR decreases to <60 mL·min −1 ·1.73 m −2 independently of other risk factors, including diabetes mellitus. [7] [8] [9] Cardiovascular events are the most frequent cause of death in patients with CKD. 10 In addition, high levels of albuminuria (urine albumin-creatinine ratio [UACR] ≥30 mg/g), a marker of kidney damage, are associated with an increased risk of all-cause and cardiovascular mortality independently of eGFR and diabetes mellitus. 8 In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with T2DM and established cardiovascular disease, treatment with the selective sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin versus placebo (given in addition to standard of care) significantly reduced the risk of 3-point major adverse cardiovascular events ([MACE] ; composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 14%. 11 This was driven by a 38% reduction in the risk of cardiovascular death. 11 Furthermore, empagliflozin reduced the risk of hospitalization for heart failure by 35%, all-cause mortality by 32%, and all-cause hospitalization by 11% compared with placebo. 11, 12 Notably, empagliflozin also reduced the risk of incident or worsening nephropathy by 39% compared with placebo, with a similar risk reduction in patients with and without prevalent kidney disease (eGFR <60 mL·min −1 ·1.73 m −2 and/or macroalbuminuria [UACR >300 mg/g]) at baseline. 13 Because SGLT2 inhibitors act on the renal proximal tubule, it is not surprising that the amount of glucose excreted via the urine with empagliflozin is directly related to renal function. 14 Clinical trials have shown that reductions in hemoglobin A 1c (HbA 1c ) with empagliflozin are attenuated in patients with reduced renal function, 15, 16 and the current US prescribing information for empagliflozin does not recommend its use in patients with eGFR <45 mL·min −1 ·1.73 m −2 . 17 On the other hand, there is some evidence that the effects of empagliflozin on other cardiovascular parameters such as systolic blood pressure (SBP) and albuminuria persist even in patients with CKD. 15, 16 Whether these nonglycemic effects of empagliflozin could alter clinical outcomes in patients with T2DM and CKD remains unknown. Here, we present further insights from the EMPA-REG OUT-COME trial focusing on cardiovascular and clinical outcomes, including cardiovascular and all-cause mortality, in participants with prevalent kidney disease at baseline.
METHODS

Trial Design
The design of the EMPA-REG OUTCOME trial has been described. 11, 18 Briefly, patients with T2DM (with HbA 1c of 7.0%-9.0% for drug-naive patients and 7.0%-10.0% for those on stable glucose-lowering therapy), established cardiovascular disease, and eGFR (according to Modification of Diet in Renal Disease equation) ≥30 mL·min −1 ·1.73 m −2 were eligible for inclusion. Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily in addition to standard of care. Background glucose-lowering therapy was to remain unchanged for the first 12 weeks after randomization, after which investigators were encouraged to adjust glucose-lowering therapy to achieve glycemic control according to local guidelines. Throughout the trial, investigators were encouraged to treat other cardiovascular risk
Clinical Perspective
What Is New?
• Empagliflozin added to standard of care reduced cardiovascular death, hospitalization for heart failure, all-cause hospitalization, and all-cause mortality compared with placebo in patients with type 2 diabetes mellitus, chronic kidney disease, and established cardiovascular disease.
• The effects on clinical outcomes with empagliflozin were independent of renal function or albuminuria status at baseline.
• The adverse event profile of empagliflozin was similar across subgroups by renal function at baseline.
• Adverse events of particular concern in this population such as urinary tract infection, acute renal failure, hyperkalemia, fractures, lower limb amputations, and hypoglycemia were not increased with empagliflozin compared with placebo.
What Are the Clinical Implications?
• Despite current standard of care, patients with kidney disease are at increased risk of cardiovascular morbidity and mortality.
• In a vulnerable population of patients with type 2 diabetes mellitus, chronic kidney disease, and established cardiovascular disease, empagliflozin improved clinical outcomes and reduced mortality.
• Another clinically relevant finding was that, despite diminishing glucose-lowering efficacy with declining renal function, other clinical parameters, including blood pressure, were improved with empagliflozin regardless of renal status at baseline. • Hence, these hypothesis-generating data suggest that empagliflozin could address a significant unmet need in patients with chronic kidney disease. • Further research is underway to substantiate these findings.
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factors to achieve optimal standard of care according to local guidelines. The trial was to continue until ≥691 patients experienced an adjudicated primary outcome event: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke . Patients who prematurely discontinued study medication continued to be followed up for ascertainment of cardiovascular outcomes and vital status. The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines and was approved by local authorities. An independent Ethics Committee or Institutional Review Board approved the clinical protocol at each participating center. Patients provided written informed consent before study entry.
Outcomes
Cardiovascular outcome events and deaths were prospectively adjudicated by Clinical Events committees. 11, 18 Definitions of the major clinical outcomes in the EMPA-REG OUTCOME trial have been published. 11, 18 All-cause hospitalization was based on adverse event reporting and was not an adjudicated outcome. Cardiovascular death, hospitalization for heart failure, all-cause hospitalization, and all-cause mortality were analyzed in the subsets of 2250 patients with and 4718 without prevalent kidney disease (eGFR <60 mL·min and/or macroalbuminuria [UACR >300 mg/g]) at baseline and are depicted for empagliflozin pooled, empagliflozin 10 mg, empagliflozin 25 mg, and placebo. In addition, we present analyses of 3-point MACE, cardiovascular death, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, all-cause hospitalization (hospitalization for any adverse event), and all-cause mortality in subgroups of patients stratified by eGFR <60 (n=1819) and ≥60 (n=5199) mL·min −1 ·1.73 m −2 at baseline. We also present changes in HbA 1c , weight, uric acid, SBP, and hemoglobin in these subgroups. Cardiovascular outcomes and all-cause mortality were further analyzed in subgroups stratified by eGFR <45, 45 to <60, 60 to <90, and ≥90 mL·min −1 ·1.73 m −2 at baseline and by UACR >300 (n=760), 30 to ≤300 (n=2063), and <30 (n=4171) mg/g at baseline.
Safety was assessed by evaluation of adverse events in subgroups stratified by eGFR <45, 45 to <60, and ≥60 mL·min −1 ·1.73 m −2 at baseline and are depicted for empagliflozin pooled, empagliflozin 10 mg, empagliflozin 25 mg, and placebo. Confirmed hypoglycemia adverse events were documented episodes with plasma glucose ≤70 mg/dL and/or requiring assistance. Events consistent with urinary tract infection, genital infection, acute renal failure, volume depletion, bone fracture, and hyperkalemia were based on searches of adverse events reported by investigators. From the trial database, we identified events consistent with lower limb amputation from events reported as adverse events, from those reported as a "medical procedure" in electronic case report forms or in investigator comments describing adverse events, and via a systematic search of serious adverse event narratives.
Statistical Analyses
Analyses were performed in the treated set (patients who received ≥1 dose of study drug [modified intent-to-treat approach]). Treatment group differences in the risk of an outcome were assessed with a Cox proportional hazards model with treatment, age, sex, baseline body mass index, baseline HbA 1c , baseline eGFR, and region as factors. Subgroup analyses stratified by eGFR (predefined), UACR (predefined), and eGFR or macroalbuminuria (post-hoc) at baseline included a test of the treatment group by subgroup interaction without adjustment for multiple testing. Data for patients who did not have an event were censored on the last day they were known to be free of the outcome. Cumulative incidence function estimates of cardiovascular death, hospitalization for heart failure, and all-cause hospitalization in patients with prevalent kidney disease were corrected for death as a competing risk. Kaplan-Meier estimates are presented for all-cause mortality in patients with prevalent kidney disease. Because of the declining numbers of patients at risk, cumulative incidence and Kaplan-Meier plots have been truncated at 48 months.
Changes in HbA 1c , weight, uric acid, SBP, and hemoglobin in subgroups by eGFR <60 and ≥60 mL·min ). Adverse events with empagliflozin and placebo in patients with eGFR <45, 45 to <60, and ≥60 mL·min −1 ·1.73 m −2 at baseline were compared post-hoc on the basis of incidence rate ratios.
RESULTS
Baseline Characteristics
In the overall trial population, baseline characteristics were balanced between the placebo and empagliflozin groups.
11 At baseline, 26% of patients had eGFR <60 mL·min
, 29% had microalbuminuria (UACR 30-≤300 mg/g), 11% had macroalbuminuria, and 32% had prevalent kidney disease (eGFR <60 mL·min −1 ·1.73 m −2 and/or macroalbuminuria). Baseline characteristics for patients with and without prevalent kidney disease at baseline are shown in Table I in the online-only Data Supplement. There were no clinically meaningful differences in baseline characteristics between the empagliflozin and placebo groups in either subgroup. Compared with patients without prevalent kidney disease at baseline, those with prevalent kidney disease were older, more likely to have had a diagnosis of T2DM for >10 years, and more likely to be treated with insulin. Greater proportions of patients with prevalent kidney disease at baseline had multivessel coronary artery disease, coronary artery bypass graft, or cardiac failure. Greater proportions of patients with prevalent kidney disease at baseline were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, diuretics, calcium channel blockers, mineralocorticoid receptor antagonists, fibrates, and vitamin K antagonists.
Outcomes in Patients With T2DM and Prevalent Kidney Disease
In both the empagliflozin and placebo groups, event rates for all outcomes presented were numerically higher in patients with than without prevalent kidney disease at baseline (Figure 1 ). In patients with prevalent kidney disease at baseline, empagliflozin reduced the risk of cardiovascular death by 29% compared with placebo (hazard ratio 
Outcomes in Subgroups Stratified by eGFR or by Albuminuria Status
In both the empagliflozin and placebo groups, event rates for all outcomes presented were numerically higher in patients with eGFR <60 mL·min The reductions in risk of 3-point MACE, cardiovascular death, all-cause mortality, hospitalization for heart failure, and all-cause hospitalization with empagliflozin versus placebo were consistent between patients with eGFR <60 and ≥60 mL·min The reductions in risk of 3-point MACE, cardiovascular death, all-cause mortality, hospitalization for heart failure, and all-cause hospitalization with empagliflozin versus placebo were consistent across patients with UACR >300, 30 to ≤300, and <30 mg/g at baseline (P>0.05 for treatment by subgroup interactions; Figure  IV in the online-only Data Supplement). There was no difference in the risk of myocardial infarction or stroke with empagliflozin versus placebo across subgroups on the basis of UACR at baseline.
Metabolic and Hemodynamic Parameters in Subgroups by eGFR
At baseline, HbA 1c and weight were similar between patients with eGFR <60 and ≥60 mL·min Table II in the online-only Data Supplement).
At baseline, serum uric acid was greater in patients with eGFR <60 than ≥60 mL·min . Serum uric acid was lower with empagliflozin than placebo over 192 weeks in both subgroups, and the difference between empagliflozin and placebo was similar in both subgroups after 12 and 164 weeks ( Figure 3 and Table  II in the online-only Data Supplement).
Baseline SBP was similar between patients with eGFR <60 and ≥60 mL·min . Empagliflozin increased hemoglobin versus placebo, with similar changes in both subgroups after 12 and 164 weeks (Figure 4 and Table II in the online-only Data Supplement).
Baseline low-density lipoprotein cholesterol was greater in patients with eGFR ≥60 than <60 mL·min Additional information on changes in HbA 1c , weight, uric acid, SBP, hemoglobin, low-density lipoprotein Table III in the onlineonly Data Supplement.
Safety and Tolerability
The adverse event profile of empagliflozin was similar in patients with eGFR <45, 45 to <60, and ≥60 mL·min −1 ·1.73 m −2 at baseline ( Figure 5 and Table IV in the online-only Data Supplement). In all subgroups, rates of adverse events consistent with genital infection were greater with empagliflozin than placebo. Urinary tract infection, volume depletion, acute renal failure, hyperkalemia, confirmed hypoglycemia, bone fracture, and lower limb amputations occurred at lower or similar rates with empagliflozin compared with placebo in patients with eGFR <45, 45 to <60, and ≥60 mL·min −1 ·1.73 m −2 ( Figure 5 ). There were no clinically relevant differences in the adverse event profile of empagliflozin between the 10-and 25-mg doses (Table IV in the online-only Data Supplement).
DISCUSSION
In the EMPA-REG OUTCOME trial, 32% of the trial population had prevalent kidney disease in addition to T2DM and established cardiovascular disease at baseline. In this vulnerable population, empagliflozin added to standard of care reduced cardiovascular death, hospitalization for heart failure, all-cause hospitalization, and all-cause mortality versus placebo. The relative reductions in risk of cardiovascular death, all-cause mortality, and hospitalization for heart failure with empagliflozin versus placebo were independent of renal function or albuminuria status at baseline and similar across the 2 doses of empagliflozin. Consistent with the analyses in the overall patient population, there was no difference in the risk of stroke or myocardial infarction between empagliflozin and placebo in patients with or without prevalent kidney disease. Our findings add to evidence showing that empagliflozin significantly slowed the progression of kidney diseases and reduced clinically relevant renal events in the overall population of the EMPA-REG OUTCOME trial. 13 Notably, empagliflozin also significantly reduced the risk for the composite renal end point (progression to macroalbuminuria, doubling of serum creatinine, initiation of renal replacement therapy, or death resulting from renal disease) versus placebo in the subgroup of patients with prevalent kidney disease at baseline (HR, 0.58; 95% CI, 0.47-0.71]). Furthermore, the renal effects of empagliflozin were consistent among subgroups of patients according to GFR or albuminuria status at baseline. 13 Observational data suggest that individuals with CKD are likely to die before they reach end-stage renal disease. 19 Here, we present the first observation from a dedicated randomized outcomes trial that identifies the potential of a therapy to alleviate the risk of premature death in patients with T2DM and CKD. The overall mortality risk was ≈2-fold higher in patients with versus without prevalent kidney disease at baseline in the EM-PA-REG OUTCOME trial. The absolute risk reductions of 2.3% and 2.7% for cardiovascular death and all-cause mortality, respectively, observed with empagliflozin in patients with prevalent kidney disease translate to a number needed to treat of 43 and 37, respectively, over the median observation time of 3.1 years to prevent 1 event. Thus, the reduction in mortality observed with empagliflozin in this trial is clinically relevant, particularly because it occurred despite the benefits of standard of care, which included high use of renin-angiotensinaldosterone system blockade, statins, and antithrombotic therapy. Underlining the vulnerability of patients with T2DM and CKD, it is notable that the mortality rate of such patients is greater than that of patients with cancer. 19 In a Canadian cohort, patients 55 years of age with eGFR of 30 to <45, 15 to <30, and <15 mL·min The magnitude of the effect of empagliflozin on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial has sparked considerable interest in the possible mechanisms responsible, [20] [21] [22] [23] particularly because significant reductions in cardiovascular or allcause mortality were not observed with another SGLT2 inhibitor, canagliflozin, in the pooled CANVAS Program (Canagliflozin Cardiovascular Assessment Study) of patients with T2DM at high cardiovascular risk. 24 Experimental data suggest that the benefit observed with empagliflozin may be attributed to its effects on the heart. 25 However, subgroup analyses from the EMPA-REG OUTCOME trial showed that empagliflozin reduced the risk of heart failure hospitalization and cardiovascular death in patients with and without investigator-reported heart failure at baseline, 12 indicating effects beyond altering impaired cardiac function.
Consistent with the results of other trials, 15, 16 the reduction in HbA 1c with empagliflozin versus placebo ob- ·1.73 m −2 at baseline. †Plasma glucose ≤70 mg/dL and/or requiring assistance. ‡Based on 79 Medical Dictionary for Regulatory Activities (MedDRA) preferred terms. §Pyelonephritis, urosepsis, or serious adverse event consistent with urinary tract infection. ǁBased on 88 MedDRA preferred terms. #Based on 8 MedDRA preferred terms. **Based on the narrow standardized MedDRA query "acute renal failure." † †Based on 62 MedDRA preferred terms. ‡ ‡Identified from events reported as adverse events, from those reported as a "medical procedure" in electronic case report forms or in investigator comments describing adverse events, and via a systematic search of serious adverse event narratives. § §Based on 2 MedDRA preferred terms.
ORIGINAL RESEARCH ARTICLE served in this trial was smaller in patients with than without impaired renal function. The effects of empagliflozin on other cardiovascular parameters in the EMPA-REG OUTCOME trial such as SBP, uric acid, and hemoglobin were similar in patients with and without CKD. This finding is consistent with a pooled analysis of phase 3 data from the empagliflozin development program comprising 2286 individuals with T2DM. This analysis indicated that, unlike HbA 1c reductions, SBP and weight reductions with empagliflozin are generally preserved in patients with CKD. 16 This evidence suggests that several pharmacodynamic properties of empagliflozin are preserved in patients with CKD, an observation that may seem paradoxical given the lower number of functioning nephrons capable of mediating these effects. The increase in mean hemoglobin of ≈1 g/dL in patients with CKD treated with empagliflozin may be of clinical relevance, especially in patients with renal anemia.
Beyond the increases in glucose excretion and osmotic diuresis related to urine output, empagliflozin has been shown to stimulate transient natriuresis. 26, 27 This has been hypothesized to result in a shift in sodium delivery from the proximal tubule to distal tubular compartments of the nephrons such as the macula densa. Sensing of sodium at this site activates a tubulo-glomerular feedback mechanism that mediates a reduction in intraglomerular pressure. 28 This renal hemodynamic effect of empagliflozin, reflected as an initial dip in eGFR after treatment initiation, is present in patients with CKD 15 and not only may benefit the low-pressure intraglomerular environment but also may influence bidirectional heart-kidney interactions, often referred to as the cardiorenal axis. 29 This is supported by evidence that empagliflozin reduces arterial stiffness and cardiac workload, 30 which may be a consequence of reduced blood pressure resulting from reduced plasma volume. The hemodynamic effects of empagliflozin may be of particular relevance in patients with CKD, in whom sodium and volume overload, associated with impaired vascular compliance and increased cardiac workload, are believed to be key contributors to the increased cardiovascular burden, including an increased risk of heart failure. 6, 10 The renal hemodynamic effects of empagliflozin appear to be reminiscent of those of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers 31 ; however, these effects of empagliflozin appear to remain operative despite background reninangiotensin-aldosterone system blocker therapy in the vast majority of patients with prevalent kidney disease.
Beyond high cardiovascular risk, CKD is associated with substantially increased rates of hospitalization and healthcare costs. [32] [33] [34] [35] In a retrospective study of patients with eGFR of 30 to 59 mL·min , 43% of patients were hospitalized over a mean observation period of 2.7 years. 33 In EMPA-REG OUTCOME, 50% of patients with baseline eGFR <60 mL·min −1 ·1.73 m −2 who received placebo were hospitalized at least once during the trial, underscoring the increased use of healthcare resources in patients with T2DM and CKD. Empagliflozin significantly reduced the risk of all-cause hospitalization in patients with prevalent kidney disease. The absolute risk reduction was 5.6%, which would translate to a number needed to treat of 18 to prevent 1 hospital admission over the median observation time of 3.1 years. Further clinical research is needed to explore whether this could translate into significant reductions in healthcare expenditure.
In the particularly vulnerable population of patients with T2DM, established cardiovascular disease, and CKD, the adverse event profile of empagliflozin was consistent with that observed in the overall trial population. Adverse events of particular concern in this population such as urinary tract infection, acute renal failure, hyperkalemia, fractures, lower limb amputations, and hypoglycemia occurred at lower or similar rates with empagliflozin compared with placebo in patients with eGFR <45, 45 to <60, and ≥60 mL·min . As observed in other trials of SGLT2 inhibitors, greater percentages of patients treated with empagliflozin than placebo had events consistent with genital infection.
Limitations of our data include the post-hoc nature of some of the analyses. Only 32% and 26% of the overall study population had prevalent kidney disease or eGFR <60 mL·min , respectively, at baseline, although this was still a substantial number of patients (n=2250 and n=1819, respectively). Exclusion of patients with eGFR <30 mL·min −1 ·1.73 m −2 limit the generalizability of our findings to patients with advanced kidney disease. Further research is required to investigate the effects of empagliflozin on cardiovascular and renal outcomes in broader populations of patients with CKD. In this regard, the recently announced outcomes trial of empagliflozin in patients with CKD with and without T2DM and further trials such as CREDENCE (Assessment of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy; NCT02065791) and DAPA-CKD (a study to evaluate the effect of dapagliflozin on renal outcomes and cardiovascular mortality in patients with chronic kidney disease; NCT03036150) are designed to explore the benefit-risk profile of different SGLT2 inhibitors in populations with more advanced kidney disease.
Conclusions
Empagliflozin added to standard of care reduced morbidity and mortality in patients with T2DM, established cardiovascular disease, and CKD. Despite diminishing glucose-lowering efficacy with declining renal function, improved clinical outcomes with empagliflozin were consistent across subgroups of patients by baseline renal function or albuminuria. Further outcome research is underway to assess whether empagliflozin could represent a treatment option to mitigate the risk of premature death and to reduce cardiovascular and healthcare burden in patients with CKD.
